2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M
Viking secures 1b supply of obesity pill candidate with $150m prepayment deal
J&J and Protagonist’s icotrokinra scores in Phase IIb UC study
Pfizer's new drug data in breast cancer draws muted response
*please scroll down for all the latest news*
